Evaluating the relationship of methadone concentrations and EDDP formation in chronic pain patients

Journal of Analytical Toxicology

Volumn 36, Issue 4, 2012, Pages 239-249

  Leimanis, Edijs ^a   Best, Brookie M ^a,b   Atayee, Rabia S ^a,c   Pesce, Amadeo J ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UCSD MEDICAL CENTER   (United States)

^d Millennium Research Institute   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDENE; CREATININE; METHADONE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; 2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE; NARCOTIC ANALGESIC AGENT; PYRROLIDINE DERIVATIVE;

ARTICLE; CHRONIC PAIN; CONCENTRATION RESPONSE; CREATININE URINE LEVEL; DRUG URINE LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; URINE PH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PH; REFERENCE VALUE; URINE;

ANALGESICS, OPIOID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC PAIN; HUMANS; HYDROGEN-ION CONCENTRATION; METHADONE; PYRROLIDINES; REFERENCE VALUES; TANDEM MASS SPECTROMETRY;

EID: 84864539688     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bks020     Document Type: Article

References (32)

1. Pergolizzi, J. et al. (2008) Opioids and the management of chronic severe pain in the elderly: Consensus statement of an international expert panel with focus on the six clinically most often used world health organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Practice, 8, 287-313.
2. Bruera, E., Neumann, C.M. (1999) Role of methadone in the management of pain in cancer patients. Oncology, 13, 1275-1282, 1285-1288, 1291.
3. Fishman, S.M. et al. (2002) Methadone reincarnated: Novel clinical applications with related concerns. Pain Medicine, 3, 339-348.
4. Trescot, A.M. et al. (2008) Opioid pharmacology. Pain Physician, 11, S133-S153.
5. Trescot, A.M. et al. (2008) Opioids in the management of chronic non-cancer pain: An update of American Society of Interventional Pain Physicians' (ASIPP) guidelines. Pain Physician, 11, S5-S62.
6. Baselt, R.C. (2008) Disposition of toxic drugs and chemicals in man, 8th edition. Biomedical Publications, Foster City, CA, 489-492, 941-945.
7. Ferrari, A. et al. (2004) Methadone-Metabolism, pharmacokinetics and interactions. Pharmacological Research: The Official Journal of the Italian Pharmacological Society, 50, 551-559.
8. Iribarne, C. et al. (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chemical Research in Toxicology, 9, 365-373.
9. Crettol, S. et al. (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clinical Pharmacology and Therapeutics, 78, 593-604.
10. Hines, S. et al. (2008) Management of acute pain in methadone maintenance therapy in-patients. Drug and Alcohol Review, 27, 519-523.
11. Kadiev, E. et al. (2008) Role of pharmacogenetics in variable response to drugs: Focus on opioids. Expert Opinion on Drug Metabolism, 4, 77-91.
12. Totah, R.A. et al. (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology, 108, 363-374.
13. Chang, Y. et al. (2011) Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: A reconciliation. Basic and Clinical Pharmacology & Toxicology, 108, 55-62.
14. Chou, R. (2009) 2009 Clinical guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain. Polskie Archiwum Medycyny Wewnetrznej, 119, 469-477.
15. Cook, J.D. et al. (2000) The characterization of human urine for specimen validity determination in workplace drug testing: A review. Journal of Analytical Toxicology, 24, 579-588.
16. Lafolie, P. et al. (1991) Importance of creatinine analyses of urine when screening for abused drugs. Clinical Chemistry, 37, 1927-1931.
17. Cone, E.J., Lange, R., Darwin, W.D. (1998) In vivo adulteration: Excess fluid ingestion causes false-negative marijuana and cocaine urine test results. Journal of Analytical Toxicology, 22, 460-473.
18. Cone, E.J. et al. (2009) Normalization of urinary drug concentrations with specific gravity and creatinine. Journal of Analytical Toxicology, 33, 1-7.
19. Needleman, S.B., Porvaznik, M., Ander, D. (1992) Creatinine analysis in single collection urine specimens. Journal of Forensic Sciences, 37, 1125-1133.
20. Kreek, M.J. (1973) Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. New York State Journal of Medicine, 73, 2773-2777.
21. Anggard, E. et al. (1979) Pharmacokinetics of methadone during maintenance therapy: Pulse labeling with deuterated methadone in the steady state. European Journal of Clinical Pharmacology, 16, 53-57.
22. Wolff, K. et al. (1991) Methadone concentrations in plasma and their relationship to drug dosage. Clinical Chemistry, 37, 205-209.
23. Preston, K.L. et al. (2003) Methadone and metabolite urine concentrations in patients maintained on methadone. Journal of Analytical Toxicology, 27, 332-341.
24. Kell, M.J. (1994) Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting. Journal of Addictive Diseases, 13, 5-26.
25. Boulton, D.W., Arnaud, P., DeVane, C.L. (2001) Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clinical Pharmacology and Therapeutics, 70, 48-57.
26. Danielson, T.J., Mozayani, A., Sanchez, L.A. (2008) Methadone and methadone metabolites in postmortem specimens. Forensic Science, Medicine, and Pathology, 4, 170-174.
27. Woodahl, E.L., Ho, R.J. (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Current Drug Metabolism, 5, 11-19.
28. Li, Y. et al. (2008) Interindividual variability of methadone response: Impact of genetic polymorphism. Molecular Diagnosis and Therapy, 12, 109-124.
29. Eap, C.B., Buclin, T., Baumann, P. (2002) Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clinical Pharmacokinetics, 41, 1153-1193.
30. Lee, J., Franz, L., Goforth, H.W. (2009) Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. Psychosomatics, 50, 638-639.
31. McCance-Katz, E.F., Sullivan, L.E., Nallani, S. (2010) Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. American Journal of Addiction, 19, 4-16.
32. McCance-Katz, E.F., Mandell, T.W. (2010) Drug interactions of clinical importance with methadone and buprenorphine. American Journal of Addiction, 19, 2-3.